New Mesothelioma Clinical Trial Hopes to Improve Chemotherapy

This study is part of a broad development program that includes a number of additional planned studies." TRACON Pharmaceuticals develops novel targeted cancer therapies. Its TRC105 antibody is directed at renal cell carcinoma and hepatocellular carcinoma. This clinical trial with TRC102 is one of five nationally involving methoxyamine, but one of more than 200 trials for mesothelioma. (Source: Asbestos and Mesothelioma News)

from MedWorm: Mesothelioma http://www.medworm.com/index.php?rid=164063608&cid=c_409_55_f&fid=36962&url=http%3A%2F%2Fwww.asbestos.com%2Fnews%2F2016%2F01%2F27%2Fmesothelioma-clinical-trial-more-effective-chemotherapy%2F